A study published in the journal Rheumatology states that patients with "Raised inflammatory markers at the start of [TNF-a Inhibitor] therapy" had greater improvement in regards to disease activity.

Overall, the authors write that, "The majority of patients receiving anti-TNF therapy for AS during routine care demonstrated an improvement in disease activity."

To read the study abstract click here.

STAY INFORMED! Stay up-to-date on all the latest news and information regarding AS and related diseases with our news magazine, Spondylitis Plus. Your subscription comes free with SAA membership, so click here to join today!